169 related articles for article (PubMed ID: 29395830)
1. Labile plasma iron as an indicator of patient adherence to iron chelation treatment.
Steinberg-Shemer O; Yacobovich J; Cohen M; Cabantchik IZ; Tamary H
Blood Cells Mol Dis; 2018 Jul; 71():1-4. PubMed ID: 29395830
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
3. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
[TBL] [Abstract][Full Text] [Related]
4. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
[TBL] [Abstract][Full Text] [Related]
6. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
Wahidiyat PA; Wijaya E; Soedjatmiko S; Timan IS; Berdoukas V; Yosia M
Blood Cells Mol Dis; 2019 Jul; 77():67-71. PubMed ID: 30978615
[TBL] [Abstract][Full Text] [Related]
7. LPI-labile plasma iron in iron overload.
Cabantchik ZI; Breuer W; Zanninelli G; Cianciulli P
Best Pract Res Clin Haematol; 2005 Jun; 18(2):277-87. PubMed ID: 15737890
[TBL] [Abstract][Full Text] [Related]
8. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
[TBL] [Abstract][Full Text] [Related]
9. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
[TBL] [Abstract][Full Text] [Related]
10. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
11. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
12. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
13. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
14. Labile plasma iron in iron overload: redox activity and susceptibility to chelation.
Esposito BP; Breuer W; Sirankapracha P; Pootrakul P; Hershko C; Cabantchik ZI
Blood; 2003 Oct; 102(7):2670-7. PubMed ID: 12805056
[TBL] [Abstract][Full Text] [Related]
15. Iron metabolism in kidney allograft recipients: still a mystery?
Malyszko J; Głowińska I; Malyszko JS; Levin-Iaina N; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Oct; 43(8):2973-5. PubMed ID: 21996204
[TBL] [Abstract][Full Text] [Related]
16. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
17. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation.
Naoum FA; Espósito BP; Ruiz LP; Ruiz MA; Tanaka PY; Sobreira JT; Cançado RD; de Barros JC
Acta Haematol; 2014; 131(4):222-6. PubMed ID: 24335268
[TBL] [Abstract][Full Text] [Related]
18. Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation.
Bnaya A; Shavit L; Malyszko JS; Malyszko J; Slotki I
Ther Apher Dial; 2020 Aug; 24(4):416-422. PubMed ID: 31762187
[TBL] [Abstract][Full Text] [Related]
19. Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation.
Essmann S; Heestermans M; Dadkhah A; Janson D; Wolschke C; Ayuk F; Kröger NM; Langebrake C
Transplant Cell Ther; 2023 Jan; 29(1):42.e1-42.e6. PubMed ID: 36241148
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
